|
Oxford Biomedica (LSE: OXB) a
leading gene therapy company, announces today that
changes to its Board of Directors, which were announced
on 15 April 2008, have become effective. The Company
also announces today the promotion of Nick Woolf to
Chief Business Officer, effective immediately. These
changes reflect the Company's stage of growth and are
aligned with its strategic focus on clinical development
and commercialisation of its lead drug candidates.
Nick Woolf, Oxford BioMedica's Senior Vice President,
Corporate Strategy, is appointed to the newly created
position of Chief Business Officer. In this role, Nick
will manage the Company's business activities, including
partnering, strategic transactions, capital markets and
investor relations. He joined Oxford BioMedica in 2002
and became an Executive Director in 2005. Prior to
Oxford BioMedica, Nick was Director and Head of European
Biotechnology Research at ABN AMRO and was previously at
Robertson Stephens, Nomura and SBC Warburg.
In
relation to Stuart Naylor's appointment to the Board, as
per the announcement dated 15 April 2008, there are no
further details requiring disclosure under Paragraph
9.6.13 R of the Financial Services Authority Listing
Rules.
|
Oxford BioMedica
plc
|
|
|
|
For further information please
contact:
|
|
|
Oxford BioMedica plc
Mike McDonald,
Chief Executive Officer
Nick Woolf,
Chief Business Officer
|
Tel: +44 (0)1865 783 000
|
|
JPMorgan Cazenove Limited
James Mitford/Gina Gibson
|
Tel: +44 (0)20 7588 2828
|
|
City/Financial Enquiries
Lisa Baderoon/Mark
Court/Mary-Jane
Johnson
Buchanan Communications
|
Tel: +44 (0)20 7466 5000
|
|
Scientific/Trade Press Enquiries
Holly
Griffiths/Katja
Stout/Claire
Mosley
College Hill
|
Tel: +44
(0)20 7457 2020
|
|
US
Enquiries
Thomas Fechtner
The Trout Group LLC
|
|
|
|
|
All rights reserved